SG11201809344QA - Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde - Google Patents

Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde

Info

Publication number
SG11201809344QA
SG11201809344QA SG11201809344QA SG11201809344QA SG11201809344QA SG 11201809344Q A SG11201809344Q A SG 11201809344QA SG 11201809344Q A SG11201809344Q A SG 11201809344QA SG 11201809344Q A SG11201809344Q A SG 11201809344QA SG 11201809344Q A SG11201809344Q A SG 11201809344QA
Authority
SG
Singapore
Prior art keywords
court
suite
jaime
therapeutics
south san
Prior art date
Application number
SG11201809344QA
Inventor
Zhe Li
Nathan Guz
Yiyang Shao
Julieana Cocuz
Markus Frieser
George Yiannikouros
Liang Liao
Original Assignee
Global Blood Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Global Blood Therapeutics Inc filed Critical Global Blood Therapeutics Inc
Publication of SG11201809344QA publication Critical patent/SG11201809344QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/65—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by splitting-off hydrogen atoms or functional groups; by hydrogenolysis of functional groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
    • C07C47/56—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
    • C07C47/56—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing hydroxy groups
    • C07C47/565—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing hydroxy groups all hydroxy groups bound to the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
    • C07C47/575—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)

Abstract

FIG12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 16 November 2017 (16.11.2017) WIPO I PCT omit VIII mum 0 VIII mil °nom mil (10) International Publication Number WO 2017/197083 Al C (51) International Patent Classification: A61K 31/44 (2006.01) C07D 401/04 (2006.01) C07D 231/02 (2006.01) (21) International Application Number: PCT/US2017/032104 (22) International Filing Date: 11 May 2017 (11.05.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/335,583 12 May 2016 (12.05.2016) US (71) Applicant: GLOBAL BLOOD THERAPEUTICS, INC. [US/US]; 400 East Jamie Court Suite 101, South San Fran- cisco, CA 94080 (US). (72) Inventors: LI, Zhe; c/o Global Blood Therapeutics, Inc., 400 E. Jaime Court Suite 101, South San Francisco, CA 94080 (US). GUZ, Nathan; c/o Global Blood Therapeutics, Inc., 400 E. Jaime Court Suite 101, South San Francisco, CA 94080 (US). SHAO, Yiyang; c/o Global Blood Therapeu- tics, Inc., 400 E. Jaime Court Suite 101, South San Francis- co, CA 94080 (US). COCUZ, Julieana; c/o Global Blood Therapeutics, Inc., 400 E. Jaime Court Suite 101, South San Francisco, CA 94080 (US). FRIESER, Markus; c/o Glob- al Blood Therapeutics, Inc., 400 E. Jaime Court Suite 101, South San Francisco, CA 94080 (US). YIANNIKOUROS, George, Petros; c/o Global Blood Therapeutics, Inc., 400 E. Jaime Court Suite 101, South San Francisco, CA 94080 (US). LIAO, Liang; c/o Global Blood Therapeutics, Inc., 400 E. Jaime Court Suite 101, South San Francisco, CA 94080 (US). (74) Agent: CLARK, Kevin et al.; Jones Day, 250 Vesey Street, New York, NY 10281-1047 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (54) Title: PROCESS FOR SYNTHESIZING 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)-PYRIDIN-3- YL)METHOXY)BENZALDEHYDE 1-1 00 O N 01 1-1 1 -1 (57) : Disclosed herein are processes for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1H- pyrazol-5-y1)-pyridin-3- O yl)methoxy)benzaldehyde (also referred to herein as Compound (I)) and intermediates used in such processes. Compound (I) binds to \" hemoglobin and increases it oxygen affinity and hence can be useful for the treatment of diseases such as sickle cell disease. [Continued on next page] WO 2017/197083 Al MIDEDIMOMOIDEIROIDEMOMOIROBIRMODEVOIMIE SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3))
SG11201809344QA 2016-05-12 2017-05-11 Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde SG11201809344QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662335583P 2016-05-12 2016-05-12
PCT/US2017/032104 WO2017197083A1 (en) 2016-05-12 2017-05-11 Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde

Publications (1)

Publication Number Publication Date
SG11201809344QA true SG11201809344QA (en) 2018-11-29

Family

ID=60268009

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201809344QA SG11201809344QA (en) 2016-05-12 2017-05-11 Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG10201912288VA SG10201912288VA (en) 2016-05-12 2017-05-11 Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201912288VA SG10201912288VA (en) 2016-05-12 2017-05-11 Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde

Country Status (20)

Country Link
US (5) US10077249B2 (en)
EP (2) EP3454854B1 (en)
JP (2) JP7398193B2 (en)
KR (3) KR20230146119A (en)
CN (2) CN109152770A (en)
AR (1) AR108435A1 (en)
AU (2) AU2017261730B2 (en)
CA (1) CA3023662A1 (en)
DK (1) DK3454854T3 (en)
EA (2) EA037014B1 (en)
ES (1) ES2881426T3 (en)
HR (1) HRP20211193T1 (en)
HU (1) HUE055045T2 (en)
IL (3) IL297055B2 (en)
MX (3) MX387149B (en)
PL (1) PL3454854T3 (en)
PT (1) PT3454854T (en)
SG (2) SG11201809344QA (en)
TW (3) TWI663160B (en)
WO (1) WO2017197083A1 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2797416T1 (en) 2011-12-28 2017-12-29 Global Blood Therapeutics, Inc. Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
WO2013102145A1 (en) 2011-12-28 2013-07-04 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
WO2014145040A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
CN111454200A (en) 2013-03-15 2020-07-28 全球血液疗法股份有限公司 Compounds and their use for modulating hemoglobin
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
AU2014237340C1 (en) 2013-03-15 2018-11-08 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
AP2015008718A0 (en) 2013-03-15 2015-09-30 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
EA201992707A1 (en) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. COMPOUNDS AND THEIR APPLICATIONS FOR HEMOGLOBIN MODULATION
RS61653B2 (en) 2014-02-07 2024-10-31 Global Blood Therapeutics Inc Crystalline polymorph of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
MA41841A (en) 2015-03-30 2018-02-06 Global Blood Therapeutics Inc ALDEHYDE COMPOUNDS FOR THE TREATMENT OF PULMONARY FIBROSIS, HYPOXIA, AND AUTOIMMUNE AND CONNECTIVE TISSUE DISEASES
BR112018011272A2 (en) 2015-12-04 2018-11-21 Global Blood Therapeutics Inc 2-hydroxy-6 - ((2- (1-isopropyl-1h-pyrazol-5-yl) pyridin-3-yl) methoxy) benzaldehyde dosage regimens
TWI663160B (en) 2016-05-12 2019-06-21 全球血液治療公司 Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
TW202332423A (en) 2016-10-12 2023-08-16 美商全球血液治療公司 Tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
TN2019000290A1 (en) 2017-03-20 2021-05-07 Forma Therapeutics Inc Pyrrolopyrrole compositions as pyruvate kinase (pkr) activators
CN113226356B (en) 2018-09-19 2025-03-04 诺沃挪第克健康护理股份公司 Pyruvate kinase R
MA53668B1 (en) 2018-09-19 2024-06-28 Novo Nordisk Health Care Ag TREATMENT OF SICKLE CELL DISEASE WITH A COMPOUND ACTIVATING PYRUVATE KINASE R
US11014884B2 (en) 2018-10-01 2021-05-25 Global Blood Therapeutics, Inc. Modulators of hemoglobin
TWI841630B (en) 2018-11-19 2024-05-11 美商全球血液治療公司 Modulators of hemoglobin
WO2020127924A1 (en) 2018-12-21 2020-06-25 Bionice, S.L.U. Process and intermediates for the preparation of voxelotor
EP3898608A1 (en) * 2018-12-21 2021-10-27 Crystal Pharma, S.A.U. Process and intermediates for the synthesis of voxelotor
EP3693364A1 (en) * 2019-02-11 2020-08-12 Sandoz Ag Crystalline salts of a hemoglobin s allosteric modulator
JP7312317B2 (en) * 2019-09-12 2023-07-20 アシムケム ラボラトリーズ （フーシン） カンパニー リミテッド Continuous production apparatus for 2,6-dihydroxybenzaldehyde and its use
AU2020349555A1 (en) 2019-09-19 2022-04-07 Forma Therapeutics, Inc. Activating Pyruvate Kinase R
IL292982A (en) 2019-11-19 2022-07-01 Global Blood Therapeutics Inc Methods of Administering Voxlotor
GB202002560D0 (en) * 2020-02-24 2020-04-08 Johnson Matthey Plc Crystalline forms of voxelotor, and processes for the preparation thereof
IT202000009970A1 (en) * 2020-05-05 2021-11-05 Dipharma Francis Srl PROCEDURE FOR THE PREPARATION OF A DRUG FOR THE TREATMENT OF SICKLE CELL ANEMIA
WO2021224280A1 (en) * 2020-05-05 2021-11-11 Dipharma Francis S.R.L. Synthesis of a sickle cell disease agent and intermediates thereof
IT202000025135A1 (en) * 2020-10-23 2022-04-23 Dipharma Francis Srl PROCEDURE FOR THE PREPARATION OF A DRUG FOR THE TREATMENT OF SICKLE CELL ANEMIA
CN112047924B (en) * 2020-10-10 2023-04-18 山东汇海医药化工有限公司 Preparation method of Wo Keluo polypeptide
WO2022099064A2 (en) * 2020-11-06 2022-05-12 Global Blood Therapeutics, Inc. Process for preparation of 2-hydroxy-6-((2-(1-isopropyl- 1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
CN116710441A (en) * 2020-11-06 2023-09-05 全球血液疗法公司 Method for preparing 2-hydroxy-6- ((2- (1-isopropyl-1H-pyrazol-5-yl) pyridin-3-yl) methoxy) benzaldehyde
US11611474B2 (en) 2020-12-28 2023-03-21 Juniper Networks, Inc. Edge controller with network performance parameter support
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
IL312447A (en) 2021-11-05 2024-06-01 Global Blood Therapeutics Inc Methods of treating sickle cell disease with voxelotor

Family Cites Families (256)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL103316C (en) 1956-02-13 1900-01-01
BE787580A (en) 1971-08-13 1973-02-14 Hoechst Ag FURANNE DERIVATIVE PREPARATION PROCESS
BE787576A (en) 1971-08-13 1973-02-14 Hoechst Ag BENZOFURANE DERIVATIVES AND THEIR USE AS OPTICAL BLASTERS
GB1409865A (en) 1973-02-13 1975-10-15 Science Union & Cie Dihydropyridines derivatives their preparation and pharmaceu tical compositions containing them
GB1593417A (en) 1976-12-22 1981-07-15 Squibb & Sons Inc Carbocyclic-fused pyrazolopyridine derivatives
US4062858A (en) 1976-12-22 1977-12-13 E. R. Squibb & Sons, Inc. Derivatives of 5,6-dihydrobenzo[5,6]cyclohepta[1,2-b]pyrazolo[4,3-e]pyridin-11(1H)-ones and 11(1H)-imines
EP0010063B1 (en) 1978-10-04 1982-12-29 Ciba-Geigy Ag Process for the preparation of furanyl-benzazoles
DE2853765A1 (en) 1978-12-13 1980-06-26 Bayer Ag METHOD FOR PRODUCING BENZIMIDAZOLYLBENZOFURANES
DE2904829A1 (en) 1979-02-08 1980-08-14 Bayer Ag METHOD FOR PRODUCING BENZIMIDAZOLYLBENZOFURANE
DE3061269D1 (en) 1979-06-29 1983-01-13 Wellcome Found Substituted phenol ethers, their preparation, intermediates therefor, pharmaceutical compositions containing them and the preparation thereof
GB2090830B (en) 1980-12-18 1984-09-26 Wellcome Found Formyl ether derivatives
JPS5929667A (en) 1982-08-13 1984-02-16 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
US4478834A (en) 1983-02-11 1984-10-23 Usv Pharmaceutical Corporation Dihydropyridines and their use in the treatment of asthma
GB8402740D0 (en) 1984-02-02 1984-03-07 Scras Furo-(3 4-c)-pyridine derivatives
JPS6140236A (en) 1984-08-02 1986-02-26 Yamanouchi Pharmaceut Co Ltd Hydroquinone derivative
DE3431004A1 (en) 1984-08-23 1986-03-06 Hoechst Ag, 6230 Frankfurt NEW 3-PYRIDYL COMPOUNDS AND METHOD FOR THEIR PRODUCTION
DD226590A1 (en) 1984-09-07 1985-08-28 Univ Leipzig MEANS FOR PHAGENHEMMUNG IN MICROBIAL PRODUCTION PROCESSES
GB8603475D0 (en) 1986-02-12 1986-03-19 Glaxo Group Ltd Chemical compounds
DK111387A (en) 1986-03-05 1987-09-06 Otsuka Pharma Co Ltd CARBOSTYRIL DERIVATIVES AND SALTS THEREOF, MEDICINE CONTAINING SUCH DERIVATIVES AND PROCEDURES FOR THE PREPARATION OF THE DERIVATIVES
US4831041A (en) 1986-11-26 1989-05-16 Fujisawa Pharmaceutical Co., Ltd. Imidazopyridine compounds and processes for preparation thereof
EP0278686A1 (en) 1987-02-07 1988-08-17 The Wellcome Foundation Limited Pyridopyrimidines methods for their preparation and pharmaceutical formulations thereof
DD258226A1 (en) 1987-03-05 1988-07-13 Fahlberg List Veb PROCESS FOR PRODUCING AROXYMETHYLCHINOXALINES
JPH07121937B2 (en) 1987-03-18 1995-12-25 大塚製薬株式会社 Carbostyril derivative
JPS63258463A (en) 1987-04-14 1988-10-25 Kumiai Chem Ind Co Ltd 2-phenoxypyrimidine derivatives and herbicides
GB8711802D0 (en) 1987-05-19 1987-06-24 Fujisawa Pharmaceutical Co Dithioacetal compounds
GB8718940D0 (en) 1987-08-11 1987-09-16 Glaxo Group Ltd Chemical compounds
US4920131A (en) 1987-11-03 1990-04-24 Rorer Pharmaceutical Corp. Quinoline derivatives and use thereof as antagonists of leukotriene D4
JP2650038B2 (en) 1988-01-27 1997-09-03 サントリー株式会社 Pyrrolitidine compounds and uses thereof
EP0336369A1 (en) 1988-04-04 1989-10-11 E.R. Squibb & Sons, Inc. 3-Acylamino-1-[[[(substituted sulfonyl)amino]carbonyl]amino]2-azetidinones
US4952574A (en) 1988-09-26 1990-08-28 Riker Laboratories, Inc. Antiarrhythmic substituted N-(2-piperidylmethyl)benzamides
IE81170B1 (en) 1988-10-21 2000-05-31 Zeneca Ltd Pyridine derivatives
DD276480A1 (en) 1988-10-26 1990-02-28 Fahlberg List Veb PROCESS FOR THE PREPARATION OF NAPHTHO / 2,1-B / FUR-2-YLCHINOXALINES
DD276479A1 (en) 1988-10-26 1990-02-28 Fahlberg List Veb PROCESS FOR THE PREPARATION OF BENZO / B / FUR-2-YLCHINOXALINES
US5236917A (en) 1989-05-04 1993-08-17 Sterling Winthrop Inc. Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof
IT1230859B (en) 1989-06-05 1991-11-08 Corvi Camillo Spa 2 ALCHYLYLPHENOLS SUBSTITUTED FOR ANTI-INFLAMMATORY ACTION, PROCEDURE FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
GB2244054B (en) 1990-04-19 1994-04-06 Ici Plc Pyridine derivatives
IL98526A0 (en) 1990-06-18 1992-07-15 Merck & Co Inc Pyridones,processes for their preparation and pharmaceutical compositions containing them
KR100196559B1 (en) 1990-06-19 1999-06-15 기따사또 이찌로 Pyridine derivatives with angiotensin ii antagonism
NL9001752A (en) 1990-08-02 1992-03-02 Cedona Pharm Bv NEW 1,4-DIHYDROPYRIDINE DERIVATIVES.
IL99731A0 (en) 1990-10-18 1992-08-18 Merck & Co Inc Hydroxylated pyridine derivatives,their preparation and pharmaceutical compositions containing them
US5403816A (en) 1990-10-25 1995-04-04 Kumiai Chemical Industry Co., Ltd. Picolinic acid derivative and herbicidal composition
JPH05301872A (en) 1992-04-23 1993-11-16 Kumiai Chem Ind Co Ltd Picolinic acid derivative and herbicide
WO1992013841A1 (en) 1991-02-08 1992-08-20 Byk Gulden Lomberg Chemische Fabrik Gmbh Complexing agents
JPH0641118A (en) 1991-05-31 1994-02-15 Kumiai Chem Ind Co Ltd Picolinic acid derivative and herbicide
US5185251A (en) 1991-06-07 1993-02-09 Merck & Co., Inc. Microbial transformation of a substituted pyridinone using actinoplanacete sp. MA 6559
JP2600644B2 (en) 1991-08-16 1997-04-16 藤沢薬品工業株式会社 Thiazolyl benzofuran derivative
FR2680512B1 (en) 1991-08-20 1995-01-20 Adir NOVEL 2,4-THIAZOLIDINEDIONE DERIVATIVES, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
US5202243A (en) 1991-10-04 1993-04-13 Merck & Co., Inc. Method of hydroxylating 3-[2-(benzoxazol-2-yl)ethyl]-5-ethyl-6-methyl-2-(1H)-pyridinone by incubation with liver slices
GB9203798D0 (en) 1992-02-21 1992-04-08 Fujisawa Pharmaceutical Co Quinolylbenzofuran derivatives,processes for preparation thereof and pharmaceutical composition comprising the same
WO1994001406A1 (en) 1992-07-01 1994-01-20 Byk Gulden Lomberg Chemische Fabrik Gmbh Contrast agents for mr diagnosis
US5290941A (en) 1992-10-14 1994-03-01 Merck & Co., Inc. Facile condensation of methylbenzoxazoles with aromatic aldehydes
CA2135474C (en) 1993-04-07 1998-11-10 Shingo Yano Thiazolidine derivatives and pharmaceutical compositions containing the same
DE4318550A1 (en) 1993-06-04 1994-12-08 Boehringer Mannheim Gmbh Arylidene-4-oxo-2-thioxo-3-thiazolidinecarboxylic acids, process for their preparation and pharmaceutical compositions containing them
US5534529A (en) 1993-06-30 1996-07-09 Sankyo Company, Limited Substituted aromatic amides and ureas derivatives having anti-hypercholesteremic activity, their preparation and their therapeutic uses
JPH0725882A (en) 1993-07-07 1995-01-27 Res Dev Corp Of Japan INTERMEDIATE FOR PRODUCING ACROMELIC ACID B AND E AND METHOD FOR PRODUCING THE SAME
ATE180780T1 (en) 1993-08-05 1999-06-15 Hoechst Marion Roussel Inc 2-(PIPERIDINE-4-YL, PYRIDINE-4-YL AND TETRAHYDROPYRIDINE-4-YL)-BENZOFURAN-7-CARBAMAT DERIVATIVES, THEIR PREPARATION AND USE AS ACETYLCHOLINESTERASE INHIBITORS
EP0640609A1 (en) 1993-08-24 1995-03-01 Ono Pharmaceutical Co., Ltd. Fused phenol derivatives having inhibitory activity on TXA2 synthetase, and 5-lipoxygenase and scavenging activity on oxygen species
US5965566A (en) 1993-10-20 1999-10-12 Enzon, Inc. High molecular weight polymer-based prodrugs
US5840900A (en) 1993-10-20 1998-11-24 Enzon, Inc. High molecular weight polymer-based prodrugs
US5880131A (en) 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US5605976A (en) 1995-05-15 1997-02-25 Enzon, Inc. Method of preparing polyalkylene oxide carboxylic acids
WO1995014015A1 (en) 1993-11-19 1995-05-26 Ciba-Geigy Ag Benzothiophene derivatives possessing a methoxyimino substituent as microbicides
EP0658559A1 (en) 1993-12-14 1995-06-21 Chemisch Pharmazeutische Forschungsgesellschaft m.b.H. Thienothiazin derivatives, process for their preparation and their use as 5-dipoxygenase and cyclooxygenase inhibitors
PT750631E (en) 1994-02-14 2000-07-31 Merrell Pharma Inc NEW MERCAPTO-AACETILAMIDE-1,3,4,5-TETRAHYDRO-BENZO) AZEPIN-3-ONA UTEIS DISSULFURET DERIVATIVES AS ENCEPHALINASE AND ACE INHIBITORS
GB9420557D0 (en) 1994-10-12 1994-11-30 Zeneca Ltd Aromatic compounds
DE4442050A1 (en) 1994-11-25 1996-05-30 Hoechst Ag Heterospiro compounds and their use as electroluminescent materials
US5650408A (en) 1995-06-07 1997-07-22 Karanewsky; Donald S. Thiazolo benzazepine containing dual action inhibitors
TW434240B (en) 1995-06-20 2001-05-16 Zeneca Ltd Aromatic compounds, preparation thereof and pharmaceutical composition comprising same
JP3895404B2 (en) 1996-05-17 2007-03-22 興和株式会社 Chalcone derivative and pharmaceutical containing the same
EP0923580A1 (en) 1996-07-26 1999-06-23 Dr. Reddy's Research Foundation Thiazolidinedione compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions thereof
US6630496B1 (en) 1996-08-26 2003-10-07 Genetics Institute Llc Inhibitors of phospholipase enzymes
WO1998008818A1 (en) 1996-08-26 1998-03-05 Genetics Institute, Inc. Inhibitors of phospholipase enzymes
WO1998009967A1 (en) * 1996-09-09 1998-03-12 Kyowa Hakko Kogyo Co., Ltd. Pyrrolocarbazole derivatives
CN1237166A (en) 1996-11-12 1999-12-01 诺瓦提斯公司 Pyrazole derivatives useful as herbicides
US6043389A (en) 1997-03-11 2000-03-28 Mor Research Applications, Ltd. Hydroxy and ether-containing oxyalkylene esters and uses thereof
FR2761687B1 (en) 1997-04-08 2000-09-15 Centre Nat Rech Scient QUINOLEIN DERIVATIVES, ESPECIALLY HAVING ANTIVIRAL PROPERTIES, THEIR PREPARATIONS AND THEIR BIOLOGICAL APPLICATIONS
US5760232A (en) 1997-06-16 1998-06-02 Schering Corporation Synthesis of intermediates useful in preparing bromo-substituted tricyclic compounds
US6214817B1 (en) 1997-06-20 2001-04-10 Monsanto Company Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity
US6011042A (en) 1997-10-10 2000-01-04 Enzon, Inc. Acyl polymeric derivatives of aromatic hydroxyl-containing compounds
US6111107A (en) 1997-11-20 2000-08-29 Enzon, Inc. High yield method for stereoselective acylation of tertiary alcohols
JP2002508379A (en) 1997-12-12 2002-03-19 ユーロ−セルティーク，エス．エイ． 3-Substituted adenine via 2-thioxanthine
SK12782000A3 (en) 1998-02-25 2001-04-09 Genetics Institute, Inc. Inhibitors of phospholipase a2
WO1999047529A1 (en) 1998-03-18 1999-09-23 Ariad Pharmaceuticals, Inc. Heterocyclic signal transduction inhibitors, compositions containing them
US6214879B1 (en) 1998-03-24 2001-04-10 Virginia Commonwealth University Allosteric inhibitors of pyruvate kinase
US6153655A (en) 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
GB9810860D0 (en) 1998-05-20 1998-07-22 Hoechst Schering Agrevo Gmbh Substituted pyridine and pyrimidines, processes for their preparation and their use as pesticides
JP2002517396A (en) 1998-06-04 2002-06-18 アボット・ラボラトリーズ Anti-inflammatory compounds that inhibit cell adhesion
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
GB9818627D0 (en) 1998-08-26 1998-10-21 Glaxo Group Ltd Improvements in dva vaccination
GB9823871D0 (en) 1998-10-30 1998-12-23 Pharmacia & Upjohn Spa 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents
US20030060425A1 (en) 1998-11-24 2003-03-27 Ahlem Clarence N. Immune modulation method using steroid compounds
ATE274491T1 (en) 1998-12-14 2004-09-15 Hoffmann La Roche PHENYLGLYCINE DERIVATIVES
US6544980B2 (en) 1998-12-31 2003-04-08 Aventis Pharmaceuticals Inc. N-carboxymethyl substituted benzolactams as inhibitors of matrix metalloproteinase
WO2000040564A1 (en) 1998-12-31 2000-07-13 Aventis Pharmaceuticals Inc. N-carboxymethyl substituted benzolactams as inhibitors of matrix metalloproteinase
KR20020020685A (en) 1999-03-31 2002-03-15 스타르크, 카르크 Substituted Aniline Compounds
US6251927B1 (en) 1999-04-20 2001-06-26 Medinox, Inc. Methods for treatment of sickle cell anemia
MXPA01011502A (en) 1999-05-14 2003-08-20 Boehringer Ingelheim Pharma Enzyme-activated anti-tumor prodrug compounds.
US6184228B1 (en) 1999-05-25 2001-02-06 Anadys Pharmaceuticals, Inc. Anti-sickling agents: selection methods and effective compounds
HK1045306A1 (en) 1999-06-03 2002-11-22 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
AUPQ105499A0 (en) 1999-06-18 1999-07-08 Biota Scientific Management Pty Ltd Antiviral agents
KR100731271B1 (en) 1999-06-28 2007-06-21 얀센 파마슈티카 엔.브이. Respiratory synthium virus replication inhibitor
BR0014331A (en) 1999-09-28 2003-06-10 Eisai Co Ltd Compound, squalene synthesizing enzyme inhibitor, medicinal composition, process for producing a quinuclide compound and process for preventing or curing a disease
CZ20021570A3 (en) 1999-11-05 2002-10-16 Emisphere Technologies, Inc. Phenylamincarboxylic acids and compositions for delivering active agents
AUPQ407699A0 (en) 1999-11-16 1999-12-09 Fujisawa Pharmaceutical Co., Ltd. Aminoalcohol derivatives
AU2001230537A1 (en) 2000-02-01 2001-08-14 Daiichi Pharmaceutical Co., Ltd. Pyridoxazine derivatives
US6506755B2 (en) 2000-02-03 2003-01-14 Hoffmann-La Roche Inc. Thiazolidinecarboxyl acids
AUPQ585000A0 (en) 2000-02-28 2000-03-16 Fujisawa Pharmaceutical Co., Ltd. Aminoalcohol derivatives
JP2003528068A (en) 2000-03-17 2003-09-24 コリクサ コーポレイション New amphiphilic aldehydes and their use as adjuvants and immune effectors
AUPQ841300A0 (en) 2000-06-27 2000-07-20 Fujisawa Pharmaceutical Co., Ltd. New aminoalcohol derivatives
EP1303490B1 (en) 2000-07-14 2008-07-09 F. Hoffmann-La Roche Ag N-oxides as nk1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives
AU2001281071A1 (en) 2000-08-01 2002-02-13 Gmp Companies, Inc. Ammonium salts of hemoglobin allosteric effectors, and uses thereof
US6653313B2 (en) 2000-08-10 2003-11-25 Warner-Lambert Company Llc 1,4-dihydropyridine compounds as bradykinin antagonists
JP4272338B2 (en) 2000-09-22 2009-06-03 バイエル アクチェンゲゼルシャフト Pyridine derivatives
AUPR034000A0 (en) 2000-09-25 2000-10-19 Fujisawa Pharmaceutical Co., Ltd. Aminoalcohol derivatives
WO2002051849A1 (en) 2000-12-26 2002-07-04 Daiichi Pharmaceutical Co., Ltd. Cdk4 inhibitors
US7238716B2 (en) 2000-12-28 2007-07-03 Takeda Pharmaceuticals Company Limited Alkanoic acid derivatives process for their production and use thereof
GB0102595D0 (en) 2001-02-01 2001-03-21 Virk Kuldip Smart solar
US20030022923A1 (en) 2001-03-01 2003-01-30 Medinox, Inc. Methods for treatment of sickle cell anemia
US6627646B2 (en) 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
US20030073712A1 (en) 2001-07-23 2003-04-17 Bing Wang Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods
JP2003075970A (en) 2001-08-31 2003-03-12 Konica Corp Silver halide color photographic sensitive material, color photographic sensitive material, image forming method for the same and method for creating digital image information
KR100467313B1 (en) 2001-11-22 2005-01-24 한국전자통신연구원 Red organic electroluminescent compounds, method for synthesizing the same and electroluminescent devices
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
WO2003053368A2 (en) 2001-12-19 2003-07-03 Atherogenics, Inc. Chalcone derivatives and their use to treat diseases
US20030190333A1 (en) 2002-02-04 2003-10-09 Corixa Corporation Immunostimulant compositions comprising aminoalkyl glucosaminide phosphates and saponins
US20040072796A1 (en) 2002-04-18 2004-04-15 Embury Stephen H. Method and composition for preventing pain in sickle cell patients
US6608076B1 (en) 2002-05-16 2003-08-19 Enzon, Inc. Camptothecin derivatives and polymeric conjugates thereof
GB0212785D0 (en) 2002-05-31 2002-07-10 Glaxo Group Ltd Compounds
US20060074119A1 (en) 2002-08-08 2006-04-06 Andrews Clarence W Iii Thiophene compounds
KR100942073B1 (en) 2002-08-23 2010-02-12 기린 홀딩스 가부시키가이샤 Compound having TVF β inhibitory activity and pharmaceutical composition comprising the same
EP1541564A1 (en) 2002-09-10 2005-06-15 Takeda Pharmaceutical Company Limited Five-membered heterocyclic compounds
ATE527238T1 (en) 2002-12-04 2011-10-15 Univ Virginia Commonwealth AGENT AGAINST SICKLE CELL ANEMIA
US20040181075A1 (en) 2002-12-19 2004-09-16 Weingarten M. David Process of making chalcone derivatives
JP4679155B2 (en) 2002-12-25 2011-04-27 キッセイ薬品工業株式会社 Nitrogen-containing heterocyclic derivative, pharmaceutical composition containing the same, and pharmaceutical use thereof
EP1596818B1 (en) 2003-02-24 2006-05-03 Randolph Dr. Dr. Prof. Riemschneider Cosmetic composition with a whitening effect, method for the production and use thereof
US20040186077A1 (en) 2003-03-17 2004-09-23 Medicure International Inc. Novel heteroaryl phosphonates as cardioprotective agents
ZA200507752B (en) 2003-03-28 2007-01-31 Threshold Pharmaceuticals Inc Compositions and methods for treating cancer
US7291631B2 (en) 2003-04-11 2007-11-06 Genzyme Corporation CXCR4 chemokine receptor binding compounds
MXPA05013224A (en) 2003-06-12 2006-03-09 Novo Nordisk As Pyridinyl carbamates as hormone-sensitive lipase inhibitors.
WO2005019220A2 (en) 2003-08-11 2005-03-03 Cellular Genomics Inc. Substituted imidazo[1,2-a]pyrazines as modulators of kinase activity
US7411083B2 (en) 2003-09-25 2008-08-12 Wyeth Substituted acetic acid derivatives
NZ546444A (en) 2003-11-05 2009-09-25 Hoffmann La Roche Phenyl derivatives as PPAR agonists
EP1687268A1 (en) 2003-11-10 2006-08-09 Schering Aktiengesellschaft Benzylether amine compounds useful as ccr-5 antagonists
ZA200604815B (en) 2003-12-02 2007-10-31 Celgene Corp Methods and compositions for the treatment and management of hemoglobinopathy and anemia
US7378439B2 (en) 2004-01-20 2008-05-27 Usv, Ltd. Process for the preparation of 4-(2-dipropylaminoethyl)-1,3-dihydro-2H-indol-2-one hydrochloride
CN101014571A (en) 2004-01-30 2007-08-08 默克公司 N-benzyl-3,4-dihyroxypyridine-2-carboxamide and n-benzyl-2,3-dihydroxypyridine-4- carboxamide compounds useful as HIV integrase inhibitors
GB0403038D0 (en) 2004-02-11 2004-03-17 Novartis Ag Organic compounds
AU2005221864A1 (en) 2004-03-09 2005-09-22 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa HIV integrase inhibitors
US20080132458A1 (en) 2004-03-10 2008-06-05 Threshold Pharmaceuticals, Inc. Hypoxia-Activated Anti-Cancer Agents
DE102004015226B3 (en) 2004-03-24 2005-08-25 Siemens Ag Plasma cleaning method suitable for interior surfaces of e.g. bulbs for discharge lamps, forms back pressure and ignites plasma only inside bulb
WO2005102305A2 (en) 2004-04-22 2005-11-03 Allos Therapeutics, Inc. Compositions of allosteric hemoglobin modifiers and methods of making the same
WO2006003923A1 (en) 2004-06-30 2006-01-12 Sankyo Company, Limited Substituted benzene compound
TW200606129A (en) 2004-07-26 2006-02-16 Chugai Pharmaceutical Co Ltd Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
JP2008517956A (en) 2004-10-28 2008-05-29 メディキュア・インターナショナル・インコーポレーテッド Dual antiplatelet / anticoagulant pyridoxine analogues
WO2006065204A1 (en) 2004-12-14 2006-06-22 Astrazeneca Ab Substituted aminopyridines and uses thereof
US7858788B2 (en) 2005-02-21 2010-12-28 Shionogi & Co., Ltd. Bicyclic carbamoylpyridone derivative having HIV integrase inhibitory activity
JP4874958B2 (en) 2005-03-30 2012-02-15 エーザイ・アール・アンド・ディー・マネジメント株式会社 Antifungal agents containing pyridine derivatives
GB0506677D0 (en) 2005-04-01 2005-05-11 Btg Int Ltd Iron modulators
EP3284519A1 (en) 2005-04-28 2018-02-21 VIIV Healthcare Company Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity
DE102005025989A1 (en) 2005-06-07 2007-01-11 Bayer Cropscience Ag carboxamides
JP2006342115A (en) 2005-06-10 2006-12-21 Shionogi & Co Ltd Polycyclic compound having hiv integrase inhibition activity
AU2006264649A1 (en) 2005-06-30 2007-01-11 Prosidion Limited GPCR agonists
CN100562514C (en) 2005-07-22 2009-11-25 中国科学院上海药物研究所 Substituted propionamide derivatives, preparation method and application thereof
GB0516270D0 (en) 2005-08-08 2005-09-14 Glaxo Group Ltd Novel compounds
DK1945622T3 (en) 2005-10-11 2012-04-02 Univ Pittsburgh Isotopically-labeled benzofuran compounds as imaging agents for amyloidogenic proteins
BRPI0617842A2 (en) 2005-10-27 2011-08-09 Shionogi & Co compound or a pharmaceutically acceptable salt or solvate thereof, and, pharmaceutical composition
EP1948614A2 (en) 2005-11-18 2008-07-30 Takeda San Diego, Inc. Glucokinase activators
WO2007084914A2 (en) 2006-01-17 2007-07-26 Neurocrine Biosciences, Inc. Phenoxy-substituted pyrimidines as adenosine receptor antagonists
RU2318818C1 (en) 2006-04-12 2008-03-10 Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" Azaheterocycles, combinatory library, focused library, pharmaceutical composition and method for preparing (variants)
GB0614586D0 (en) 2006-07-22 2006-08-30 Pliva Istrazivacki Inst D O O Pharmaceutical Formulation
CN101113148A (en) 2006-07-26 2008-01-30 中国海洋大学 Dioxypiperazine compounds and their preparation method and use
EP2054411B1 (en) 2006-07-27 2014-08-20 Amorepacific Corporation Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
TW200817424A (en) 2006-08-04 2008-04-16 Daiichi Sankyo Co Ltd Benzylphenyl glucopyranoside derivatives
TWI389895B (en) 2006-08-21 2013-03-21 Infinity Discovery Inc Compounds and methods for inhibiting the interaction of bcl proteins with binding partners
ES2670407T3 (en) 2006-09-03 2018-05-30 Techfields Biochem Co. Ltd Positively charged water-soluble acetaminophen prodrugs and compounds related to a very fast skin penetration rate
WO2008041118A2 (en) 2006-10-04 2008-04-10 Pfizer Products Inc. Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists
JP5271911B2 (en) 2006-10-23 2013-08-21 メルク・シャープ・アンド・ドーム・コーポレーション 2- [1-Phenyl-5-hydroxy or methoxy-4α-methyl-hexahydrocyclopenta [f] indazol-5-yl] ethylphenyl derivatives as glucocorticoid receptor ligands
FR2909379B1 (en) 2006-11-30 2009-01-16 Servier Lab NOVEL HETEROCYCLIC DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME.
CN101558038B (en) 2006-11-30 2013-05-01 国立大学法人东京工业大学 Curcumin derivative
TW200835687A (en) 2006-11-30 2008-09-01 R Tech Ueno Ltd Thiazole derivatives and their use as VAP-1 inhibitor
JP2008137914A (en) 2006-11-30 2008-06-19 Rikogaku Shinkokai β-secretase inhibitor
CA2677949C (en) 2007-02-22 2016-02-09 Paul Anthony Worthington Iminipyridine derivatives and their uses as microbiocides
TWI407960B (en) 2007-03-23 2013-09-11 Jerini Ag Small molecule bradykinin b2 receptor modulators
DK2149545T3 (en) 2007-05-22 2017-01-02 Sumitomo Chemical Co PROCEDURE FOR PREPARING A BENZALDEHYD COMPOUND
WO2009001214A2 (en) 2007-06-28 2008-12-31 Pfizer Products Inc. Thieno[2,3-d]pyrimidin-4(3h)-one, isoxazolo[5,4-d]pyrimidin-4(5h)-one and isothiazolo[5,4-d]pyrimidin-4(5h)-one derivatives as calcium receptor antagonists
WO2009011850A2 (en) 2007-07-16 2009-01-22 Abbott Laboratories Novel therapeutic compounds
JP5189165B2 (en) 2007-07-17 2013-04-24 エフ．ホフマン−ラ ロシュ アーゲー Inhibitors of 11β-hydroxysteroid dehydrogenase
PE20090506A1 (en) 2007-07-26 2009-05-28 Novartis Ag DERIVATIVES OF IMIDAZO- [1,2-b] -PYRIDAZINE AS INHIBITORS OF ALK5 AND / OR ALK4
TW200918521A (en) 2007-08-31 2009-05-01 Astrazeneca Ab Heterocyclic amides and methods of use thereof
EA201000615A1 (en) 2007-10-17 2010-12-30 Новартис Аг IMIDAZO [1,2-A] PYRIDINE DERIVATIVES APPLICABLE AS APC INHIBITORS (ACTIVIN-like KINASE)
BRPI0820112B8 (en) 2007-12-04 2021-05-25 Hoffmann La Roche isoxazole-pyridine derivatives, their use and preparation and drug processes
US7776875B2 (en) 2007-12-19 2010-08-17 Hoffman-La Roche Inc. Spiroindolinone derivatives
JP2009203230A (en) 2008-01-31 2009-09-10 Daiichi Sankyo Co Ltd Pharmaceutical composition containing benzyl phenyl glucopyranoside derivative
KR101586104B1 (en) 2008-02-14 2016-01-15 스미또모 가가꾸 가부시끼가이샤 Process for production of benzaldehyde compound
CA2720096A1 (en) 2008-04-11 2009-10-15 Institute Of Medicinal Molecular Design, Inc. Pai-1 inhibitor
US8633245B2 (en) 2008-04-11 2014-01-21 Institute Of Medicinal Molecular Design, Inc. PAI-1 inhibitor
JP2011136906A (en) 2008-04-18 2011-07-14 Otsuka Pharmaceut Co Ltd Heterocyclic compound
US8119647B2 (en) 2008-04-23 2012-02-21 Glenmark Pharmaceuticals S.A. Fused pyrimidineone compounds as TRPV3 modulators
KR101538822B1 (en) 2008-05-08 2015-07-22 노바 사우쓰이스턴 유니버시티 Specific inhibitors for vascular endothelial growth factor receptors
EP2300433A4 (en) 2008-06-04 2012-03-07 Ambrilia Biopharma Inc INHIBITORS OF HIV INTEGRASE FROM PYRIDOXINE
DE102008027574A1 (en) 2008-06-10 2009-12-17 Merck Patent Gmbh New pyrrolidine derivatives as MetAP-2 inhibitors
JP5314330B2 (en) 2008-06-16 2013-10-16 住友化学株式会社 Process for producing 2- (aryloxymethyl) benzaldehyde and its intermediate
GB0811451D0 (en) 2008-06-20 2008-07-30 Syngenta Participations Ag Novel microbiocides
AR073304A1 (en) 2008-09-22 2010-10-28 Jerini Ag MODULATORS OF THE BRADIQUININE B2 RECEPTOR OF SMALL MOLECULA
AU2009314299A1 (en) 2008-11-12 2010-05-20 Merck Sharp & Dohme Corp. Inhibitors of fatty acid binding protein (FABP)
JP2010168314A (en) * 2009-01-23 2010-08-05 Daiichi Sankyo Co Ltd Intermediate for producing benzene compound, and method for producing the same
TW201033201A (en) 2009-02-19 2010-09-16 Hoffmann La Roche Isoxazole-isoxazole and isoxazole-isothiazole derivatives
PL3222277T3 (en) 2009-03-31 2020-08-24 Ligand Pharmaceuticals Inc. BIPHENYL SULFONAMIDE ANTAGONIST FOR ENDOTELIN AND ANGIOTENSIN II RECEPTOR FOR THE TREATMENT OF GLOBAL SCLEROSIS AND IGA-induced nephropathy
WO2010129055A1 (en) 2009-05-08 2010-11-11 Tetraphase Pharmaceuticals, Inc. 8-aza tetracycline compounds
JP5739334B2 (en) 2009-08-26 2015-06-24 武田薬品工業株式会社 Fused heterocyclic derivatives and uses thereof
EP2474540A4 (en) 2009-08-31 2013-03-13 Nippon Chemiphar Co Gpr119 agonist
WO2011033045A1 (en) 2009-09-21 2011-03-24 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
HUE071632T2 (en) 2009-11-09 2025-09-28 Wyeth Llc Tablet formulations of neratinib maleate
TW201139406A (en) 2010-01-14 2011-11-16 Glaxo Group Ltd Voltage-gated sodium channel blockers
KR101698153B1 (en) 2010-04-26 2017-01-23 광주과학기술원 Novel pyridine carboxylic acid compound as a P2X1 and P2X3 receptor antagonist, the preparation method thereof and a composition containing the same
CN102232949A (en) 2010-04-27 2011-11-09 孙远 Drug dissolution increasing composition and preparation method thereof
TWI535442B (en) 2010-05-10 2016-06-01 Kyowa Hakko Kirin Co Ltd A nitrogen-containing heterocyclic compound having an action of inhibiting the production of canine erythritine
US20120122928A1 (en) 2010-08-11 2012-05-17 Bayer Cropscience Ag Heteroarylpiperidine and -Piperazine Derivatives as Fungicides
CN102116772B (en) 2010-09-28 2013-08-28 上海大学 Method for screening dihydrochalcone compound
TW201304823A (en) 2010-12-27 2013-02-01 Takeda Pharmaceutical Orally disintegrating tablet
EP2694514A2 (en) 2011-04-06 2014-02-12 Teva Pharmaceutical Industries Ltd. New intermediates and processes for preparing ticagrelor
EP3323816B1 (en) 2011-04-11 2019-07-03 Green Tech Co., Ltd. Novel pyrazole derivative
KR102381792B1 (en) 2011-09-15 2022-04-01 데메알엑스, 인크. Noribogaine salt ansolvates
US20140308260A1 (en) 2011-10-07 2014-10-16 Radiorx, Inc. Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products
WO2013102145A1 (en) 2011-12-28 2013-07-04 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
SI2797416T1 (en) 2011-12-28 2017-12-29 Global Blood Therapeutics, Inc. Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
JP5906489B2 (en) * 2012-05-18 2016-04-20 新日鉄住金化学株式会社 Porphyrin dye, dye-sensitized solar cell and photoelectric conversion element using porphyrin dye
WO2014104384A1 (en) 2012-12-27 2014-07-03 住友化学株式会社 Tetrazolinone compound and applications thereof
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US20150057251A1 (en) 2013-08-26 2015-02-26 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
JP6355711B2 (en) 2013-03-15 2018-07-11 グローバル ブラッド セラピューティクス インコーポレイテッド Compounds for the modification of hemoglobin and their use
CN111454200A (en) 2013-03-15 2020-07-28 全球血液疗法股份有限公司 Compounds and their use for modulating hemoglobin
ES2909634T3 (en) 2013-03-15 2022-05-09 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
US9802900B2 (en) 2013-03-15 2017-10-31 Global Blood Therapeutics, Inc. Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
US20140274961A1 (en) * 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
AP2015008718A0 (en) 2013-03-15 2015-09-30 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
EP2968295A1 (en) 2013-03-15 2016-01-20 Global Blood Therapeutics, Inc. Compositions and methods for the modulation of hemoglobin (s)
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
AU2014237340C1 (en) 2013-03-15 2018-11-08 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9604999B2 (en) 2013-03-15 2017-03-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US20140271591A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compositions and methods for the modulation of hemoglobin (s)
WO2014145040A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
WO2015031284A1 (en) 2013-08-26 2015-03-05 Global Blood Therapeutics, Inc. Formulations comprising wetting agents and compounds for the modulation of hemoglobin (s)
US20160207904A1 (en) 2013-08-27 2016-07-21 Global Blood Therapeutics, Inc. Crystalline 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde ansolvate salts
WO2015031285A1 (en) * 2013-08-27 2015-03-05 Global Blood Therapeutics, Inc. Crystalline 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde ansolvate salts
US20150141465A1 (en) 2013-11-18 2015-05-21 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
WO2015116061A1 (en) * 2014-01-29 2015-08-06 Global Blood Therapeutics, Inc. 1:1 adducts of sickle hemoglobin
US9248199B2 (en) 2014-01-29 2016-02-02 Global Blood Therapeutics, Inc. 1:1 adducts of sickle hemoglobin
RS61653B2 (en) 2014-02-07 2024-10-31 Global Blood Therapeutics Inc Crystalline polymorph of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
MA41841A (en) 2015-03-30 2018-02-06 Global Blood Therapeutics Inc ALDEHYDE COMPOUNDS FOR THE TREATMENT OF PULMONARY FIBROSIS, HYPOXIA, AND AUTOIMMUNE AND CONNECTIVE TISSUE DISEASES
BR112018011272A2 (en) 2015-12-04 2018-11-21 Global Blood Therapeutics Inc 2-hydroxy-6 - ((2- (1-isopropyl-1h-pyrazol-5-yl) pyridin-3-yl) methoxy) benzaldehyde dosage regimens
TWI663160B (en) 2016-05-12 2019-06-21 全球血液治療公司 Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
TW202332423A (en) 2016-10-12 2023-08-16 美商全球血液治療公司 Tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde

Also Published As

Publication number Publication date
HRP20211193T1 (en) 2021-10-29
AU2021200802B2 (en) 2022-09-29
IL284406B2 (en) 2023-03-01
AU2017261730B2 (en) 2020-11-19
IL262791B (en) 2021-07-29
AU2021200802A1 (en) 2021-03-04
DK3454854T3 (en) 2021-08-02
BR112018072351A2 (en) 2019-02-19
KR20230146119A (en) 2023-10-18
IL284406A (en) 2021-07-29
JP2019516692A (en) 2019-06-20
TWI825524B (en) 2023-12-11
HUE055045T2 (en) 2021-10-28
MX387149B (en) 2025-03-18
TW202237575A (en) 2022-10-01
AU2017261730A1 (en) 2018-11-15
KR102487509B1 (en) 2023-01-12
TW201741295A (en) 2017-12-01
US20170327484A1 (en) 2017-11-16
JP2022088564A (en) 2022-06-14
MX377901B (en) 2025-03-10
SG10201912288VA (en) 2020-02-27
IL284406B (en) 2022-11-01
KR20190005917A (en) 2019-01-16
EP3454854A1 (en) 2019-03-20
MX2021012669A (en) 2022-08-10
EA037014B1 (en) 2021-01-26
ES2881426T3 (en) 2021-11-29
EP3454854A4 (en) 2019-12-11
CA3023662A1 (en) 2017-11-16
KR20220139437A (en) 2022-10-14
WO2017197083A1 (en) 2017-11-16
TWI752307B (en) 2022-01-11
PT3454854T (en) 2021-07-30
IL297055A (en) 2022-12-01
PL3454854T3 (en) 2021-11-29
IL262791A (en) 2018-12-31
JP7398193B2 (en) 2023-12-14
IL297055B2 (en) 2024-04-01
AR108435A1 (en) 2018-08-22
CN115819400A (en) 2023-03-21
MX2020013114A (en) 2021-10-18
EP3454854B1 (en) 2021-04-28
US20220135533A1 (en) 2022-05-05
MX2018013099A (en) 2019-03-28
US20190106404A1 (en) 2019-04-11
EP3909941A1 (en) 2021-11-17
US10077249B2 (en) 2018-09-18
US10577345B2 (en) 2020-03-03
TWI663160B (en) 2019-06-21
EA201892151A1 (en) 2019-06-28
TW201932440A (en) 2019-08-16
EA202092636A1 (en) 2021-09-30
US20210284623A1 (en) 2021-09-16
US20230219922A1 (en) 2023-07-13
IL297055B1 (en) 2023-12-01
CN109152770A (en) 2019-01-04

Similar Documents

Publication Publication Date Title
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201811338VA (en) A novel botulinum neurotoxin and its derivatives
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201810600WA (en) Fxr (nr1h4) modulating compounds
SG11201809499UA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201907356SA (en) Piperidine-substituted mnk inhibitors and methods related thereto
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201807809XA (en) A transient commensal microorganism for improving gut health
SG11201807784SA (en) 3-desoxy derivative and pharmaceutical compositions thereof
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof
SG11201804704PA (en) Compositions and methods for decreasing tau expression
SG11201808592PA (en) Method for selection of high m6p recombinant proteins
SG11201810525XA (en) Anti-gitr antibodies and uses thereof
SG11201909807TA (en) Methods of manufacturing of niraparib
SG11201808566WA (en) Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide
SG11201810429UA (en) Anti-cd19 antibody formulations
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201809497RA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201810801QA (en) Brain delivery protein
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201810853UA (en) Anti-tnfrsf25 antibodies
SG11201805149XA (en) Compositions comprising 15-hepe and methods of using the same
SG11201805001UA (en) Method of treating influenza a